Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 511


Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.

Wang K, Tomaras GD, Jegaskanda S, Moody MA, Liao HX, Goodman KN, Berman PW, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Haynes BF, Cohen JI.

J Virol. 2017 Sep 12;91(19). pii: e00411-17. doi: 10.1128/JVI.00411-17. Print 2017 Oct 1.


Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.

Gilbert PB, Excler JL, Tomaras GD, Carpp LN, Haynes BF, Liao HX, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kijak GH, Tovanabutra S, Francis DP, Lee C, Sinangil F, Berman PW, Premsri N, Kunasol P, O'Connell RJ, Michael NL, Robb ML, Morrow R, Corey L, Kim JH.

PLoS One. 2017 May 11;12(5):e0176428. doi: 10.1371/journal.pone.0176428. eCollection 2017.


Herpesvirus entry mediator on radiation-resistant cell lineages promotes ocular herpes simplex virus 1 pathogenesis in an entry-independent manner.

Edwards RG, Kopp SJ, Karaba AH, Wilcox DR, Longnecker R.

MBio. 2015 Oct 20;6(5):e01532-15. doi: 10.1128/mBio.01532-15.


Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM.

Nicola AV, Ponce de Leon M, Xu R, Hou W, Whitbeck JC, Krummenacher C, Montgomery RI, Spear PG, Eisenberg RJ, Cohen GH.

J Virol. 1998 May;72(5):3595-601.


Regulation of herpes simplex virus gB-induced cell-cell fusion by mutant forms of gH/gL in the absence of gD and cellular receptors.

Atanasiu D, Cairns TM, Whitbeck JC, Saw WT, Rao S, Eisenberg RJ, Cohen GH.

MBio. 2013 Feb 26;4(2). pii: e00046-13. doi: 10.1128/mBio.00046-13.


An HSV-1 gD mutant virus as an entry-impaired live virus vaccine.

Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM.

Vaccine. 2008 Feb 26;26(9):1195-203. doi: 10.1016/j.vaccine.2007.12.032. Epub 2008 Jan 14.


A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.

Du R, Wang L, Xu H, Wang Z, Zhang T, Wang M, Ning Y, Deng F, Hu Z, Wang H, Li Y.

Antiviral Res. 2017 Nov;147:131-141. doi: 10.1016/j.antiviral.2017.10.013. Epub 2017 Oct 20.


A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.

Wang K, Goodman KN, Li DY, Raffeld M, Chavez M, Cohen JI.

J Virol. 2015 Nov 11;90(1):562-74. doi: 10.1128/JVI.01845-15. Print 2016 Jan 1.


Comparison of the antiviral potential among soluble forms of herpes simplex virus type-2 glycoprotein D receptors, herpes virus entry mediator A, nectin-1 and nectin-2, in transgenic mice.

Fujimoto Y, Tomioka Y, Ozaki K, Takeda K, Suyama H, Yamamoto S, Takakuwa H, Morimatsu M, Uede T, Ono E.

J Gen Virol. 2017 Jul;98(7):1815-1822. doi: 10.1099/jgv.0.000804. Epub 2017 Jul 24.


Interaction between herpesvirus entry mediator and HSV-2 glycoproteins mediates HIV-1 entry of HSV-2-infected epithelial cells.

Hu K, He S, Xiao J, Li M, Luo S, Zhang M, Hu Q.

J Gen Virol. 2017 Sep;98(9):2351-2361. doi: 10.1099/jgv.0.000895. Epub 2017 Aug 15.


Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.

Hensel MT, Marshall JD, Dorwart MR, Heeke DS, Rao E, Tummala P, Yu L, Cohen GH, Eisenberg RJ, Sloan DD.

J Virol. 2017 Apr 13;91(9). pii: e02257-16. doi: 10.1128/JVI.02257-16. Print 2017 May 1.


B Virus (Macacine Herpesvirus 1) Divergence: Variations in Glycoprotein D from Clinical and Laboratory Isolates Diversify Virus Entry Strategies.

Patrusheva I, Perelygina L, Torshin I, LeCher J, Hilliard J.

J Virol. 2016 Sep 29;90(20):9420-32. doi: 10.1128/JVI.00799-16. Print 2016 Oct 15.


A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only Vero cells expressing exogenous HVEM.

Wang K, Kappel JD, Canders C, Davila WF, Sayre D, Chavez M, Pesnicak L, Cohen JI.

J Virol. 2012 Dec;86(23):12891-902. doi: 10.1128/JVI.01055-12. Epub 2012 Sep 19.


The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.

Peng T, Ponce-de-Leon M, Jiang H, Dubin G, Lubinski JM, Eisenberg RJ, Cohen GH.

J Virol. 1998 Jan;72(1):65-72.


Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus.

Krummenacher C, Baribaud F, Ponce de Leon M, Baribaud I, Whitbeck JC, Xu R, Cohen GH, Eisenberg RJ.

Virology. 2004 May 1;322(2):286-99.


Herpesvirus entry mediator and nectin-1 mediate herpes simplex virus 1 infection of the murine cornea.

Karaba AH, Kopp SJ, Longnecker R.

J Virol. 2011 Oct;85(19):10041-7. doi: 10.1128/JVI.05445-11. Epub 2011 Jul 27.


Structural basis for the antibody neutralization of herpes simplex virus.

Lee CC, Lin LL, Chan WE, Ko TP, Lai JS, Wang AH.

Acta Crystallogr D Biol Crystallogr. 2013 Oct;69(Pt 10):1935-45. doi: 10.1107/S0907444913016776. Epub 2013 Sep 20.


Antibody-dependent cellular cytotoxicity against cells infected with herpes simplex virus type 1 in Igh-1 disparate congenic mice.

Tamesis RR, Rodriguez A, Hoang-Xuan T, Foster CS.

Ger J Ophthalmol. 1993 Aug;2(4-5):218-23.


Supplemental Content

Support Center